New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

Researchers have developed the first bioengineered human bone-marrow model to test CAR T-cell therapies for ­acute myeloid ...

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...

Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital cancer research, offering new insights into potential therapies for the ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six hematologic ...

A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could transform how blood cancer treatments are tested and tailored for patients.

A new systematic review shows CAR T-cell therapy delivers high remission rates, reduced disease activity, and low toxicity in ...

Biomedical research typically follows a familiar path: developing treatments that block, enhance or mutate certain signaling ...